Liraglutide, manufactured by Novo Nordisk, is the active ingredient used in two of the company’s older drugs: Saxenda, a weight loss drug, and Victoza, used to treat diabetes.
In the 56-week study, 82 children with non-monogenic, nonsyndromic obesity were randomly assigned to receive either a once-daily dose of liraglutide or a placebo along with lifestyle interventions. The results showed that the children taking liraglutide saw a 5.6% decrease in BMI on average, whereas children receiving the placebo saw a 1.6% increase in BMI.
Roy Kim, MD, a pediatric endocrinologist at Cleveland Clinic, shared concerns with NBC News regarding the long-term safety of using weight loss drugs for children, especially its potential effects on growth, bone health and the pancreas.
The trial results have led Novo Nordisk to apply for FDA approval to expand liraglutide use in younger children, the report said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
